The online version of this article (doi:10.1186/s13045-017-0501-4) contains supplementary material, which is available to authorized users.
The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies.
Patients were randomized (1:1) to receive ixazomib 4.0 mg or placebo on days 1, 8, and 15, plus lenalidomide 25 mg on days 1–21 and dexamethasone 40 mg on days 1, 8, 15, and 22, in 28-day cycles. Randomization was stratified according to number of prior therapies, disease stage, and prior proteasome inhibitor exposure. The primary endpoint was progression-free survival (PFS). In total, 115 Chinese patients were randomized (57 ixazomib-Rd, 58 placebo-Rd).
At the preplanned final analysis for PFS, after median PFS follow-up of 7.4 and 6.9 months, respectively, PFS was improved with ixazomib-Rd versus placebo-Rd (median 6.7 vs 4.0 months; HR 0.598; p = 0.035). At the preplanned final analysis of overall survival (OS), after median follow-up of 20.2 and 19.1 months, respectively, OS was improved with ixazomib-Rd versus placebo-Rd (median 25.8 vs 15.8 months; HR 0.419; p = 0.001). On the ixazomib-Rd and placebo-Rd arms, respectively, 38 (67%) and 43 (74%) patients reported grade ≥3 adverse events (AEs), 19 (33%) and 18 (31%) reported serious AEs, and 4 (7%) and 5 (9%) died on-study. The most frequent grade 3/4 AEs were thrombocytopenia (18%/7% vs 14%/5%), neutropenia (19%/5% vs 19%/2%), and anemia (12%/0 vs 26%/2%).
This study demonstrated that PFS and OS were significantly improved with ixazomib-Rd versus placebo-Rd, with limited additional toxicity, in patients with RRMM.
Additional file 1: Supplementary methods. Hou C16010 China Continuation study J Hematol Oncol. (DOCX 38 kb)13045_2017_501_MOESM1_ESM.docx
Additional file 2: Supplementary results. Hou C16010 China Continuation study J Hematol Oncol. (DOCX 40 kb)13045_2017_501_MOESM2_ESM.docx
Additional file 3: Details of all sites’ ethics committee approvals. (DOC 44 kb)13045_2017_501_MOESM3_ESM.doc
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda: National Cancer Institute; 2016. Based on November 2015 SEER data submission (Posted to the SEER web site, April 2016). National Cancer Institute. Bethesda, MD. 21-9-2016.
Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005;14(1):243–50. PubMed
Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(30):3459–66.
Millennium Pharmaceuticals Inc. NINLARO® (ixazomib) capsules, for oral use. Prescribing information, November 2016. 2016. http://www.ninlaro.com/downloads/prescribing-information.pdf. Accessed 15 Dec 2016.
Takeda Pharma A/S. NINLARO® European Public Assessment Report - Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf. Accessed 15 Dec 2016.
Nooka AK. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology (Williston Park). 2013;27(Suppl):311–8.
Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, et al. Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling. Clin Pharmacokinet. 2017. [Epub ahead of print]. doi: 10.1007/s40262-017-0526-4.
- Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
Michael J. Hanley
Helgi van de Velde
Paul G. Richardson
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II